BH3 mimetics to improve cancer therapy; mechanisms and examples
- 31 December 2007
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 10 (6), 207-217
- https://doi.org/10.1016/j.drup.2007.08.002
Abstract
No abstract availableKeywords
This publication has 114 references indexed in Scilit:
- Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesDrug Resistance Updates, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destructionBritish Journal of Cancer, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-xLJournal of the American Chemical Society, 2005
- Cancer genes and the pathways they controlNature Medicine, 2004
- Cell DeathCell, 2004
- Development of a Potent Bcl-xLAntagonist Based on α-Helix MimicryJournal of the American Chemical Society, 2002
- The Hallmarks of CancerCell, 2000